AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03275558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib 5 MG
Description: Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.
Study NCT03430752 — intervention group
Intervention type: OTHER
Intervention: questionnaires
Description: Participants were asked to respond to the questionnaires including the Chinese version of the Paediatric Quality of Life Inventory 4.0 Generic Core Scale (PedsQL 4.0), the Chinese version of the Center for Epidemiological Studies Depression Scale for Children (CES-DC), the Chinese version of Rosenberg self-esteem scale, the Chinese version of the Herth Hope Index (HHI) and the Chinese version of Resilience Scale for Children (RS10).
Study NCT03359733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 tablet.
Study NCT01482780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICSO
Description: PICSO (pressure controlled intermittent coronary sinus occlusion) will be used in the pre ECC period. The procedure of PICSO will be performed in analogy to retrograde cardioplegia.
Study NCT04454450 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: Imaging will include research PET/MRI of pelvis within 30 days of multiregion tissue collection.For research PET/MRI - standard volumes of gadolinium contrast and fluorodeoxyglucose (FDG) will be administered.
Study NCT04454450 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast enhanced CT
Description: Standard of care contrast enhanced CT
Study NCT01514318 — intervention group
Intervention type: DEVICE
Intervention: Revelation Hip Stem (Revelation)
Description: Subjects who received the Revelation Hip Stem prior to 2002 and still maintain the original device.
Study NCT02751983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT for Life
Description: A novel protocol detailing the application of Acceptance and Commitment Therapy (ACT) to recovery from suicidal crises. Consists of three modules designed to be delivered in three to four 60-minute individual talk therapy sessions. Nearly all of the metaphors and experiential exercises are adaptations of core ACT techniques included in various empirically-supported applications of ACT to other health conditions. Additionally, the adjunctive intervention is designed to augment safety planning (a hierarchical list of strategies to recognize and cope with a suicidal crisis).
Study NCT02751983 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: All participants will be able to engage in treatment as usual. Psychiatric inpatient care typically consists of behavioral mental health group and/or individual therapy and pharmacological treatment. Outpatient care is offered upon discharge. This typically consists of both group and individual therapy and medication management.
Study NCT02751983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: All participants will be able to engage in treatment as usual. Psychiatric inpatient care typically consists of behavioral mental health group and/or individual therapy and pharmacological treatment. Outpatient care is offered upon discharge. This typically consists of both group and individual therapy and medication management.
Study NCT00685932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobius Retractor
Description: The Mobius retractor is a dual ring elastic self retaining retractor that is inserted into the abdominal cavity after the peritoneal incision has been established. It is then left in place during the hysterotomy incision, delivery of the fetus, hysterotomy repair, inspection and irrigation.
Study NCT00381420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug-eluting stent
Description: sirolimus-coated Bx VELOCITY Balloon-Expandable Stent
Study NCT00381420 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bare-metal stent
Description: un-coated Bx VELOCITY Stent
Study NCT01800903 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ZN-D catheter
Description: ZN-D catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
Study NCT01800903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZN-D catheter
Description: ZN-D catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
Study NCT01800903 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ZN-C catheter
Description: ZN-C catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
Study NCT01800903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZN-C catheter
Description: ZN-C catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
Study NCT01800903 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SpeediCath catheter
Description: The Speedicath cathere is CE-marked and commercially available.
Study NCT01800903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath catheter
Description: The Speedicath cathere is CE-marked and commercially available.
Study NCT04303598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: 300mg, 1 tablet，QD
Study NCT04303598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: 300mg, 1 tablet，QD
Study NCT04303598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFV
Description: 200mg, 1 tablet，QD
Study NCT04303598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFV
Description: 200mg, 1 tablet，QD
Study NCT04303598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FNC placebo
Description: 1 tablet，QD
Study NCT04303598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3TC placebo
Description: 1 tablet，QD
Study NCT01078571 — intervention group
Intervention type: BIOLOGICAL
Intervention: adalimumab (HUMIRA®)
Description: The primary objective of the study is to evaluate the safety and tolerability of adalimumab (HUMIRA®) treatment, administered both in monotherapy and combined therapy, in rheumatoid arthritis (RA) patients under usual practice conditions.
Study NCT02213458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigated Care
Description: Navigated Care emphasizes continuous and personalized care and is based on 3 modules: the Caregiver Module that includes educational interventions and connects families with community resources, the Decision-Making Module that facilitates proactive medical, financial, and safety decisions, and the Medication Module that identifies inappropriate medication usage via pharmacist review. Innovative technology in the form of a dashboard functions as a patient care management system used by Care Team Navigators (CTNs).
Study NCT04847908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single high-intensity interval exercise intervention
Description: Study participants perform a single bout of exercise on a cycle ergometer (high-intensity interval exercise intervention) within the first and third cycle of chemotherapy. Following a 2 minute warm-up, the interval protocol comprises 10 intervals à 15 seconds with high intensity and 60 seconds low intensity in-between. Blood samples are taken at t0 pre-exercise (after a 10 minute rest) and at t1 immediately post-exercise via central catheter (Hickman/port).
Study NCT04301102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemosphere platform® together with the FloTrac Acumen IQ® sensor
Description: Clinical platform that, analyzing the pulse wave contour, obtained from the previously catheterized radial artery, is able to make available to the clinician both a continuous monitoring of blood pressure and advanced hemodynamic parameters that help patient management. It incorporates predictive parameters such as the hypotension prediction index and decision support parameters such as dynamic arterial elastance and maximum dP / dT.~It also has the possibility of assessing regional oxygen saturation, measured by near-infrared light photoplethysmography, and the sensor can be applied in different locations (cerebral, muscular ...).
Study NCT04301102 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hemosphere platform® together with the FloTrac® sensor
Description: Clinical platform that, analyzing the pulse wave contour, obtained from the previously catheterized radial artery, is able to make available to the clinician both a continuous monitoring of blood pressure and advanced hemodynamic parameters that help patient management.~It also has the possibility of assessing regional oxygen saturation, measured by near-infrared light photoplethysmography, and the sensor can be applied in different locations (cerebral, muscular ...).
Study NCT00635323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan plus capecitabine
Description: Irinotecan 200-250 mg/m2 intravenous infusion over 30 to 90 minutes on day 1 of a 3-week cycle. Capecitabine 1000 mg/m2 oral tablet twice daily for 14 days followed by a 7 day rest throughout the treatment period for
Study NCT01721109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVG/COBI/FTC/TDF
Description: 150/150/200/300 mg STR administered orally once daily with food
Study NCT01176409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Valacyclovir will be used at two different dosages (1g po BID and 500mg po BID) to be used for 12 weeks. Supplied as 500mg caplets.
Study NCT01176409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: Valacyclovir will be used at two different dosages (1g po BID and 500mg po BID) to be used for 12 weeks. Supplied as 500mg caplets.
Study NCT01176409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, supplied as caplets identical in appearance, odour and taste to valacyclovir 500mg caplets.
Study NCT00006092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Study NCT01481961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: After locating the left DLPFC, treatment with active rTMS will be directed by 20-minute session during which pulse trains of 5 seconds of 10 Hz spaced 25 seconds (2 trains of pulses per minute or 40 pulse trains per session). Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during rTMS for any side effects or adverse events.
Study NCT05673772 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short-course radiotherapy
Description: 25 Gy in 5 fractions for 5 days
Study NCT05673772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Oxaliplatin 85 mg/m2, Levoleucovorin 200mg (or Leucovroin, Leucosodium 400mg)/m2, 5- FU 400 mg/m2, and continuous 5- FU 2,400 mg/m2 for 46 hours
Study NCT05673772 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiotherapy
Description: 45\~50.4 Gy/25fr with concurrent use of either capecitabine or 5-FU+leucovorin(or levoleucovorin or leucosodium)
Study NCT05673772 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TME surgery
Description: TME surgery
Study NCT05673772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME surgery
Description: TME surgery
Study NCT00398749 — intervention group
Intervention type: DRUG
Intervention: Epoetin alfa
Description: 40,000 IU once weekly, variable treatment length
Study NCT02316717 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMM-124E
Description: IMM-124E
Study NCT02316717 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT02333916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: overfeeding + exercise pre-training
Study NCT02333916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fitness training
Study NCT02333916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: overfeeding + exercise post-training
Study NCT02591628 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HCTZ prescription conversion to chlorthalidone
Description: The intervention is simply a prescription conversion and the main outcome is whether or not patients accept the conversion and treatment with chlorthalidone.
Study NCT01950546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanosilver fluoride
Description: The product will be applied in the volunteers in the morning, before the first class, in relative isolation, made with cotton rolls and Vaseline to protect the soft tissue. It will apply 30mg of the product with microbrush, previously standardized in a pilot study on cervical vestibular surfaces of incisors and canines healthy, on a total of 8 teeth, 4 upper and 4 lower. After a period of 7 days,the cervical dental biofilms will be collect, third on the buccal surfaces of incisors and / or canines upper and lower, with the aid of sterile spatulas.
Study NCT00261924 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transfusion of Pathogen Inactivated Platelets stored for 6-7 days
Description: pathogen inactivation of platelets for transfusion
Study NCT00261924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transfusion of Pathogen Inactivated Platelets stored for 6-7 days
Description: pathogen inactivation of platelets for transfusion
Study NCT03268967 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured admission procedure
Description: A structured ICU admission was inspired by principles of Crisis Resource Management and simulation training of ICU staff members. The Principles of Crisis Resource Management consisted of a treatment manual, a learning video, clear precise communication tool based on Identification-Situation-Background-Analysis-Recommendations (ISBAR) and Closed loop, actions cards, and ABCDE-evaluation of the patient including debriefing, and training in the simulation environment.
Study NCT03339375 — intervention group
Intervention type: DEVICE
Intervention: esophageal Doppler
Description: Goal directed fluid therapy using dynamic parameters from esophageal Doppler
Study NCT00650039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, placebo BID by mouth on Days 2 to 5.
Study NCT00650039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg once daily (QD) by mouth on Days 2 to 5.
Study NCT00650039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg twice daily (BID) by mouth on Days 2 to 5.
Study NCT01565135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal Vaccine Program
Description: Efforts will be made to collaborate with private ob/gyn offices to develop a multimodal intervention to improve patients'immunization rates. As part of the overall intervention, intervention practices will agree to 1) purchase, stock, and administer influenza, HPV, and Tdap vaccines, if not already doing so and 2) track patients' vaccination status. In addition, intervention strategies adopted by intervention settings to improve immunization rates may include:~* Patient education regarding the importance of vaccination, including encouragement of vaccination for family members~* Practice-based reminder/recall~* Seek to decrease missed opportunities for immunization by using either or both of the following: provider prompts and/or provider education and feedback
Study NCT02423265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Ranolazine: 500 mg twice day, up-titrated after 1 week to 1000 mg twice a day
Study NCT02423265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo: up-titration after 1 week
Study NCT02064738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams
Study NCT01486017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral
Study NCT02148835 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sausage: Triomeg
Description: Commercial sausages enriched with 330 - 510 mg EPA+DHA / 100 g Approximate average composition of active product per 80 g Sausage (Triomeg): 250 mg EPA+DHA as ethyl-ester Energy content 500 kJ (120 kcal), protein 12 g, Carbohydrates 0.8 g, total fat 9 g, of which 2.8 g saturated fatty acids, 4.5 g monounsaturates, 1.4 g polyunsaturates. sodium 0.66 g.
Study NCT02148835 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sausage: Control
Description: Control sausage: as active, but no EPA+DHA ethyl-ester.
Study NCT04623580 — intervention group
Intervention type: DEVICE
Intervention: Surgical inguinal or femoral hernia repair
Description: Surgical inguinal or femoral hernia repair (primary or mesh)
Study NCT03982329 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: navigated repetitive transcranial magnetic stimulation
Study NCT03982329 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Study NCT03982329 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: physical therapy
Study NCT01221974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Essure Micro Insert
Study NCT02420496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteral fish oil
Study NCT02420496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid
Study NCT02420496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02531165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Analgesia protocol using Fentanyl (initial dose: 50-100 mcg, additional doses of 25 mcg every 2-5 minutes to achieve adequate sedation, if required).
Study NCT02531165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Analgesia protocol using Morphine (initial dose: 4-8 mg, additional doses of 2 mg every 5-15 minutes to achieve adequate sedation, if required).
Study NCT02531165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Pre-hospital Ticagrelor loading dose of 180 mg administered orally, followed by 90 mg bid
Study NCT02531165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 500 mg loading dose orally (or intravenously), followed by 100 mg od
Study NCT02531165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractioned Heparin
Description: 5'000 IU loading dose intravenously, additional doses to achieve an ACT >250 sec during PCI are allowed.
Study NCT02531165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary PCI
Description: Primary PCI with stent implantation according to the guidelines of the European Society of Cardiology.
Study NCT02797262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proteus digital health feedback (PDHF) system
Description: Building on the available Proteus devices, the investigators will design and create a PDHF system to transmit the adherence data using mobile technology to allow treatment monitoring that is, direct confirmation of the type, dose, date and time of oral pharmaceutical ingestion using wirelessly observed therapy (WOT).
Study NCT00841438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotinab
Description: Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
Study NCT00841438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clotinab
Description: Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
Study NCT01043965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 850mg
Study NCT01445392 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multicycle SS1P
Description: Assigned dose level of SS1(dsFv)PE38 on days 1, 3 \&amp; 5 of a 21 day cycle for 2 cycles
Study NCT01445392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m\^2 on day 1 of each 21 day cycle until disease progression
Study NCT01445392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m\^2 on day 1 of each 21 day cycle until disease progression
Study NCT01445392 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single cycle SS1P
Description: Patients 1 - 3 of single cycle cohort. 45 mcg/kg of SS1(dsFv)PE38 on 4 or 5 days (depending on dose level) of cycle 1 only.
Study NCT00844792 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E
Description: Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
Study NCT00844792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice a day with meals.
Study NCT03372512 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bioimpedance spectroscopy
Description: Fluid overload will be assessed by bioimpedance spectroscopy